Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q3 FY26 Earnings Presentation
40 slides from Blue Jet Healthcare's earnings presentation, Feb 13, 2026
Slide 1: Exchange filing cover letter
February 13, 2026 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Analysts/Investors Presentation on Financial Results fo
Slide 2: Investor Presentation Q3 & 9M FY26
Investor Presentation Q3 & 9M FY26 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Content
Table of Content 1 Q3 & 9M FY26 Financials 2 Company at a Glance 3 Contrast Media Intermediates 4 High Intensity Sweeteners 5 Pharma Intermediates & API 6 R&D Capabilities 7 Growth Strategy 8 Management and Board of Directors 3
Slide 5: Q3 & 9M FY26 Financials
: ‘| a 4 x ! Q3 & 9M FY26 Ky Z ~ B. : , 4 % 4 ae % se Financials —
Slide 6: Q3 FY26 vs Q2 FY26 (QoQ) Earnings Highlights
Q3 FY26 vs Q2 FY26 (QoQ) Earnings Highlights Financial Highlights ✓ Revenue from Operation in Q3 FY26 is Rs. 1,924 mn, EBITDA Rs. 469 mn (24% Margin) and PAT Rs. 402 mn (21% Margin) ✓ Revenue from Operation in Q2 FY26 was Rs. 1,655 mn, EBITDA Rs. 549 mn (33% Margin) and PAT Rs. 521 mn (32% Margin) ✓
Slide 7: Q3 FY26 vs Q3 FY25 (YoY) Earnings Highlights
Q3 FY26 vs Q3 FY25 (YoY) Earnings Highlights Financial Highlights ✓ Revenue from Operation in Q3 FY26 is Rs.1,924 mn, EBITDA Rs. 469 mn (24% Margin) and PAT Rs. 402 mn (21% Margin) ✓ Revenue from Operation in Q3 FY25 was Rs. 3,184 mn, EBITDA Rs. 1,240 mn (39% Margin) and PAT Rs. 990 mn (31% Margin)
Slide 8: 9M FY26 Earnings Highlights
9M FY26 Earnings Highlights Financial Highlights ✓ Revenue from Operation for 9M FY26 is Rs. 7,127 mn, EBITDA Rs. 2,228 mn (31% Margin) and PAT Rs. 1,835 mn (26% Margin) ✓ Revenue from Operation for 9M FY25 was Rs 6,895 mn, EBITDA Rs. 2,378 mn (34% Margin) and PAT Rs. 1,951 mn (28% Margin) ✓ YoY Rev
Slide 9: Q3 & 9M FY26 Earnings Highlights: Business Updates
Q3 & 9M FY26 Earnings Highlights Business Updates ✓ Company completed possession of land near Vizag by executing Registered Sale deed and taking formal possession of land ✓ Company executed & registered lease agreement for setting up a R&D center at Hyderabad, a three storied building having built u
Slide 10: Q3 FY26 vs Q3 FY25 Financial Performance – Key Metrics
Q3 FY26 Vs Q3 FY25 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY -30.8% -0.4% -72.6% -89.1% -39.7% Growth: Q3 FY25 Q3 FY26 3,168 1,911 1,249 1,244 1,465 371 257 401 82 9 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Oth
Slide 11: 9M FY26 vs 9M FY25 Financial Performance – Key Metrics
9M FY26 Vs 9M FY25 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) YoY -8.8% -0.2% 11.0% 29.1% 3.4% Growth: 9M FY25 9M FY26 6,857 7,092 3,028 3,023 2,663 2,955 1,038 946 128 168 High-intensity sweetners Contrast media intermediates Pharma intermediates and API O
Slide 12: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Mn) Q3 FY26 Q2 FY26 QoQ Q3 FY25 YoY 9M FY26 9M FY25 YoY Revenue from Operations 1,924 1,655 16.3% 3,184 -39.6% 7,127 6,895 3.4% Cost Of Goods Sold 928 579 1,444 3,336 3,077 Gross Profit 996 1,076 -7.5% 1,740 -42.8% 3,790 3,818 -0.7% Gross Margin 51.7% 65.0%
Slide 13: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations** – Growth Trends (Rs Mn) CAGR: 3.4% 7.8% 82.4% 269.2% 26.2% 10,243 7,185 7,084 7,092 6,768 4,778 5,070 4,799 4,622 4,942 3,536 4,039 3,023 2,955 1,575 1,759 1,282 1,335 987 946 418 412 340 947 1.33 3 16 55 247 168 High-inten
Slide 14: Financials for the last five years
Financials for the last five years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 9MFY26 Particulars (Rs. Mn) FY21 FY22 FY23 FY24 FY25 H1FY26 I. Assets Revenue from Operations 4,989 6,835 7,210 7,116 10,300 7,127 Propert
Slide 15: Shareholder Information
Shareholder Information Shareholding as on 31st December 2025 Share Information as on 31st December 2025 NSE Ticker BLUEJET Others BSE Ticker 544009 14.4% FII Market Cap (INR Cr) (BSE) 9,197 1.1% DII % free-float 20.2% 4.7% Free-float market cap (INR Cr) 1,857 Cash & Cash Equivalents + Treasury 3,41
Slide 16: Company at a Glance
. » gf Z 4 Company ata > ata Glance v SS 2
Slide 17: Our Journey
Our Journey • Established Jet Chemicals • Began manufacturing high- • Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit I) saccharin and its salts building block (5- NIPA) 1968 1970 2000 • Commenced semi- automated manufacturing •
Slide 18: Who we are
Who we are A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration, Development, Manufacturing” to CDMO business. 17
Slide 19: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance 511 1,177.9 KL INR 10,299.9 mn INR 3,777.3 mn Commercialized product reaction capacity across Revenue (FY25) (19.9% EBITDA (FY25) (36.7% portfolio (FY25) 3 facilities (FY25) FY21-25 CAGR) margin) Key metrics INR 2,848 mn 3.97x 35.8% 30.9% Cash and Cash Equivalents + F
Slide 20: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs ◼ Contrast media are agents used in medical ◼ High-intensity sweetener business involves ◼ Collaboration with innovator pharmaceutical imaging to enhance the visibility of body tissu
Slide 21: Contrast Media Intermediates
3 Contrast Media Intermediates 20
Slide 22: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers What is contrast media? Types of contrast media ◼ Chemical agents that enhances the contrast of an imaging ◼ X-ray / Computed Tomography (CT) contrast agents: Iodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media ag
Slide 23: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Highly concentrated and dominated by multi-national corporations Player 1 Others 17% 25% Global Forecast US$9.7bn By 2029 Player 2 Collectively hold ~75% of the global sales of contrast 20% Player 4 (CAGR: 7.5%) media formulations1 11% Player
Slide 24: High entry barriers for key intermediates’ vendors
High entry barriers for key intermediates’ vendors Characteristics of the Contrast Media Intermediate Blue Jet's positioning Contrast Media market product category performance ✓ More than two decades of experience CAGR: 3.4% ✓ 75%+ of exports of a selected contrast media Strict internal standards in
Slide 25: Key benefits
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product development and process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in ei
Slide 26: High Intensity Sweeteners
4 High Intensity Sweeteners 25
Slide 27: Blue Jet’s positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Products ◼ Adherence to strict internal standards to ensure consistency in quality, performance, CAGR: 7.8% taste, and impurity profile Revenue (INR mn) ◼ Multiple product
Slide 28: Pharma Intermediates & API
5Pharma Intermediates & API 27
Slide 29: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product Category Key trends in Pharma Intermediates and CDMO market Revenue and capacity utilization predictability Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO ◼ Enables asset light model and ability to
Slide 30: Overview of Blue Jet’s Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product Category Pharma Intermediate and APIs ◼ Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity product category performance sweetener business ◼ Key focus areas include hi
Slide 31: Leverage long-standing customer relationships to enter adjacencies in pharma intermediates and API
Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category Focus on three niche areas in providing CDMO services Blue Jet’s positioning Investigational new drugs and new chemical Leverage long-standing relationships with innovator e
Slide 32: R&D Capabilities
6 R&D Capabilities 31
Slide 33: Our R&D framework
Our R&D framework R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research Method Characterization of Polymorphism Pharmaceutical salt High pressure Literature search deve
Slide 34: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks Focus on enhancing through tree plantations energy efficiency Effluent treatment plants with Minimi
Slide 35: Growth Strategy
ly. 7 Fe Growth Strategy
Slide 36: Our strategies
Our strategies Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to invest in R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity customer rel
Slide 37: Management and Board of Directors
8 Management and Board of Directors 36
Slide 38: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team Akshay Bansarilal Shiven Akshay Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President – Research and Executi
Slide 39: Management team (cont’d) and Independent board of directors
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors Popat B Kedar Sweta Poddar Girish Paman Preeti Gautam Divya Sameer Priyanka Yadav Executive Director Company Secretary and Vanvari Mehta Momaya Independ
Slide 40: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLU